WO2021231827A3 - Sirna sequences targeting coronavirus-2 - Google Patents
Sirna sequences targeting coronavirus-2 Download PDFInfo
- Publication number
- WO2021231827A3 WO2021231827A3 PCT/US2021/032391 US2021032391W WO2021231827A3 WO 2021231827 A3 WO2021231827 A3 WO 2021231827A3 US 2021032391 W US2021032391 W US 2021032391W WO 2021231827 A3 WO2021231827 A3 WO 2021231827A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sirna sequences
- sequences targeting
- compositions
- cov
- sars
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Provided herein are compositions and methods useful for silencing RNA encoded by SARS-CoV-2. The compositions and methods can be used either in vitro (e.g., for research purposes), or in vitro (e.g., for therapeutic purposes). When administered to subjects who are afflicted with COVID-19, the compositions provided herein may facilitate recovery and/or ameliorate symptoms cause by SARS-CoV-2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063025220P | 2020-05-15 | 2020-05-15 | |
US63/025,220 | 2020-05-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2021231827A2 WO2021231827A2 (en) | 2021-11-18 |
WO2021231827A3 true WO2021231827A3 (en) | 2022-02-17 |
Family
ID=76306019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/032391 WO2021231827A2 (en) | 2020-05-15 | 2021-05-14 | Sirna sequences targeting coronavirus-2 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021231827A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021236763A2 (en) * | 2020-05-20 | 2021-11-25 | Nitto Denko Corporation | dsRNA DIRECTED TO CORONAVIRUS PROTEINS |
US20230047473A1 (en) * | 2021-07-14 | 2023-02-16 | Toagosei Co., Ltd. | siRNA based on RNA sequence of SARS-CoV-2 and use thereof |
EP4151730A1 (en) * | 2021-09-15 | 2023-03-22 | Medesis Pharma | Treatment of covid-19 with reverse micelle system comprising unmodified oligonucleotides |
CN114703147A (en) * | 2022-04-18 | 2022-07-05 | 扬州大学 | anti-SARS-CoV-2 broad-spectrum neutralization monoclonal antibody and hybridoma cell strain, detection kit and application thereof |
WO2023207615A1 (en) * | 2022-04-26 | 2023-11-02 | 南京明德新药研发有限公司 | Class of double-stranded rnai compounds containing overhang consisting of natural nucleotides |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
WO2012142622A1 (en) | 2011-04-15 | 2012-10-18 | Molecular Transfer, Inc. | Agents for improved delivery of nucleic acids to eukaryotic cells |
US10538784B2 (en) | 2016-03-01 | 2020-01-21 | Molecular Transfer, Inc. | Plant virus movement proteins and methods of using the same |
US10036024B2 (en) | 2016-06-03 | 2018-07-31 | Purdue Research Foundation | siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD) |
-
2021
- 2021-05-14 WO PCT/US2021/032391 patent/WO2021231827A2/en active Application Filing
Non-Patent Citations (8)
Title |
---|
CHOWDHURY UMAR FARUQ ET AL: "A Computational Approach to Design Potential siRNA Molecules as a Prospective Tool for Silencing Nucleocapsid Phosphoprotein and Surface Glycoprotein Gene of SARS-CoV-2", BIORXIV 2020.04.10.036335, 21 April 2020 (2020-04-21), pages 1 - 12, XP055825705, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.04.10.036335v2.full.pdf> [retrieved on 20210719], DOI: 10.1101/2020.04.10.036335 * |
CYNTHIA LIU ET AL: "Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases", ACS CENTRAL SCIENCE, vol. 6, no. 3, 12 March 2020 (2020-03-12), pages 315 - 331, XP055724944, ISSN: 2374-7943, DOI: 10.1021/acscentsci.0c00272 * |
FARUQ CHOWDHURY UMAR ET AL: "Supplementary Table 5: A Computational Approach to Design Potential siRNA Molecules as a Prospective Tool for Silencing Nucleocapsid Phosphoprotein and Surface Glycoprotein Gene of SARS-CoV-2", 21 April 2020 (2020-04-21), pages 1 - 4, XP055825903, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.04.10.036335v2.supplementary-material?versioned=true> [retrieved on 20210720] * |
FARUQ CHOWDHURY UMAR ET AL: "Supplementary Table 7: A Computational Approach to Design Potential siRNA Molecules as a Prospective Tool for Silencing Nucleocapsid Phosphoprotein and Surface Glycoprotein Gene of SARS-CoV-2", 21 April 2020 (2020-04-21), pages 1 - 4, XP055825908, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.04.10.036335v2.supplementary-material?versioned=true> [retrieved on 20210720] * |
HODGSON JOHN: "The pandemic pipeline", NATURE BIOTECHNOLOGY, GALE GROUP INC, NEW YORK, vol. 38, no. 5, 20 March 2020 (2020-03-20), pages 523 - 532, XP037154993, ISSN: 1087-0156, [retrieved on 20200320], DOI: 10.1038/D41587-020-00005-Z * |
JIANG YUANYUAN ET AL: "Repurposing therapeutics to identify novel inhibitors targeting 2'-O-ribose methyltransferase nsp16 of SARS-CoV-2", 1 May 2020 (2020-05-01), XP055852254, Retrieved from the Internet <URL:https://pdfs.semanticscholar.org/12a2/99c451b073596c37e9c1531d11fe14f5f9b5.pdf?_ga=2.154067056.912084237.1634547312-779291575.1634547312> [retrieved on 20211018] * |
LIU CYNTHIA ET AL: "Table S1. Distribution of RNAi patents related to SARS and MERS in the CAS content collection Patent Number RNAi type Target CAS Patent Title Organization", RESEARCH AND DEVELOPMENT ON THERAPEUTIC AGENTS AND VACCINES FOR COVID-19 AND RELATED HUMAN CORONAVIRUS DISEASES, 12 March 2002 (2002-03-12), XP055817418, Retrieved from the Internet <URL:https://pubs.acs.org/doi/10.1021/acscentsci.0c00272> [retrieved on 20210623] * |
V. D. MENACHERY ET AL: "Attenuation and Restoration of Severe Acute Respiratory Syndrome Coronavirus Mutant Lacking 2'-O-Methyltransferase Activity", JOURNAL OF VIROLOGY, vol. 88, no. 8, 29 January 2014 (2014-01-29), pages 4251 - 4264, XP055215583, ISSN: 0022-538X, DOI: 10.1128/JVI.03571-13 * |
Also Published As
Publication number | Publication date |
---|---|
WO2021231827A2 (en) | 2021-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021231827A3 (en) | Sirna sequences targeting coronavirus-2 | |
AU2018240515A1 (en) | Nucleic acids encoding CRISPR-associated proteins and uses thereof | |
MX2019002904A (en) | High purity rna compositions and methods for preparation thereof. | |
ZA201908445B (en) | Recombinant adenoviruses carrying transgenes | |
UA89957C2 (en) | Chimeric adenoviruses for use in cancer treatment | |
WO2010033798A3 (en) | Live bacterial vaccines resistant to carbon dioxide (co2), acidic ph and/or osmolarity for viral infection prophylaxis or treatment | |
UA104634C2 (en) | Pegylated l-asparaginase | |
MX339205B (en) | Stabilized liquid and lyophilized adamts13 formulations. | |
WO2007057763A3 (en) | Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant | |
EP2700708A3 (en) | Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination | |
MX2009005849A (en) | Compositions and methods to treat cancer with cupredoxins and cpg rich dna. | |
TW200738253A (en) | Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine | |
EP4282472A3 (en) | Methods of treating fabry disease in patients having a mutation in the gla gene | |
MX337041B (en) | Strains and methods for improving ruminant health and/or performance. | |
PH12015502500A1 (en) | Bacteriophage therapy | |
BR112014029954A2 (en) | treatment of solid tumors using coenzyme q10 | |
EP2518150A3 (en) | 5'Triphosphate oligonucleotide with blunt end and uses thereof | |
MX2017013564A (en) | Glucopyranosyl lipid a and peanut allergen formulations for sublingual administration. | |
WO2009098464A3 (en) | Use of g-rich oligonucleotides for treating neoplastic diseases | |
WO2004071430A3 (en) | RNAi TARGETING OF VIRUSES | |
BR112015001859A2 (en) | inflammation treatment using serelaxine | |
MX2008008768A (en) | Treatment of hiv. | |
GB0418388D0 (en) | Cell therapy | |
WO2019098759A3 (en) | Transformed human cell and use thereof | |
MX2022006547A (en) | Methods for expanding î³î´ t-cell populations with multivalent agents and compositions thereof. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21730738 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21730738 Country of ref document: EP Kind code of ref document: A2 |